Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings (MEDP)
NASDAQ:MEDP
MEDP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$250.05 - $459.77
Previous CloseN/A
Volume64.09K
Average Volume (3M)596.13K
Market Cap
$8.53B
Enterprise Value$9.19B
Total Cash (Recent Filing)$14.88M
Total Debt (Recent Filing)$377.88M
Price to Earnings (P/E)22.2
Beta1.20
Next Earnings
Jul 28, 2025EPS Estimate
2.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.10
Shares Outstanding30,228,415
10 Day Avg. Volume854,701
30 Day Avg. Volume596,132
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)N/A
Price to Sales (P/S)4.68
Price to Cash Flow (P/CF)13.00
P/FCF Ratio13.00
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.00
Enterprise Value/Ebitda19.34
Forecast
1Y Price Target
$311.00Price Target Upside7.04% Upside
Rating ConsensusHold
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue of $559 million came in above the $530 million estimate, contributing to the top-line beat.
Sales OutlookMedpace raised its 2025 sales outlook by $30 million at the midpoint and raised its EPS target by $0.34 at the midpoint.
Stock RepurchaseThe company repurchased roughly $390 million worth of shares and announced the approval of an additional $1.0 billion to its stock-repurchase program.
Bears Say
Biotech FundingThe challenging biotech funding and uncertain regulatory environment may lead to slower trial activity and more restricted biotech investment.
Bookings PerformanceBookings expectations were missed for the fifth consecutive quarter, leading to a downgrade based on a challenging macro environment and funding issues.
Hiring And PipelineManagement lowering hiring growth expectations indicates that MEDP's weaker B2B was primarily driven by a pipeline gap caused by pre-backlog cancels.
---
Ownership Overview
19.52% Insiders
23.95% Mutual Funds
1.39% Other Institutional Investors
34.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MEDP FAQ
What was Medpace Holdings’s price range in the past 12 months?
Medpace Holdings lowest stock price was $250.05 and its highest was $459.77 in the past 12 months.
What is Medpace Holdings’s market cap?
Medpace Holdings’s market cap is $8.53B.
When is Medpace Holdings’s upcoming earnings report date?
Medpace Holdings’s upcoming earnings report date is Jul 28, 2025 which is in 94 days.
How were Medpace Holdings’s earnings last quarter?
Medpace Holdings released its earnings results on Apr 21, 2025. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.06 by $0.61.
Is Medpace Holdings overvalued?
According to Wall Street analysts Medpace Holdings’s price is currently Undervalued.
Does Medpace Holdings pay dividends?
Medpace Holdings does not currently pay dividends.
What is Medpace Holdings’s EPS estimate?
Medpace Holdings’s EPS estimate is 2.99.
How many shares outstanding does Medpace Holdings have?
Medpace Holdings has 30,228,415 shares outstanding.
What happened to Medpace Holdings’s price movement after its last earnings report?
Medpace Holdings reported an EPS of $3.67 in its last earnings report, beating expectations of $3.06. Following the earnings report the stock price went down -2.322%.
Which hedge fund is a major shareholder of Medpace Holdings?
Currently, no hedge funds are holding shares in MEDP
---
Medpace Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$311.00 (7.04% Upside)
$311.00 (7.04% Upside)
Blogger Sentiment
Bullish
MEDP Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 80.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.64%
12-Months-Change
Fundamentals
Return on Equity
65.82%
Trailing 12-Months
Asset Growth
5.66%
Trailing 12-Months
Company Description
Medpace Holdings
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
---
MEDP Company Deck
---
MEDP Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there was notable growth in revenue and net income, the company faced significant challenges with declining net new business awards, elevated cancellations, and a decrease in EBITDA margin. The guidance for 2025 reflects these challenges, with potential for only modest growth.Read More>---
MEDP Revenue Breakdown
98.00% U.S.
2.00% Other
---
MEDP Stock 12 Month Forecast
Average Price Target
$311.00
▲(7.04% Upside)
Technical Analysis
Best Analysts Covering MEDP
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-15.50%
reiterated a buy rating 16 days ago
Copying Ann Hynes's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -15.50% per trade.
---